The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ribamide     1-[(2R,3R,4S,5R)-3,4- dihydroxy-5...

Synonyms: Viramide, Virazide, Virazole, Rebetol, Ribamidil, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Rebetol


High impact information on Rebetol

  • At the end of 4 weeks, all patients were offered 48 weeks of treatment with IFN-alpha/RBV [11].
  • Inhibition of inosine monophosphate dehydrogenase (IMPDH) is one of several proposed mechanisms of action for ribavirin (RBV), a critical component of the current treatment for chronic hepatitis C (CHC) [11].
  • HCV-infected LT patients with at least 6 months of follow-up following end-of-therapy (EOT) received combination therapy of ribavirin (Rbvr) + standard (n=31)/pegIFN (n=36) between 1999 and 2004 (95% genotype 1) [12].
  • Successful treatment of giant cell hepatitis with Rebetron (interferon/ribavirin) [13].
  • OBJECTIVE: The aim of this study is to report the clinical response observed in a U.S. veteran population with hepatitis C to combination therapy with Rebetron (interferon/ribavirin) outside of a controlled study environment [5].

Biological context of Rebetol


Associations of Rebetol with other chemical compounds

  • At week 1, serum HCV RNA levels and changes in alanine aminotransferase levels relative to baseline could identify likely responders better than plasma ribavirin levels [15].

Gene context of Rebetol


Analytical, diagnostic and therapeutic context of Rebetol

  • CONCLUSIONS: Our data confirm that the combination of interferon alfa-2b and tribavirin is well tolerated and feasible in patients with HIV-HCV co-infection and it can be associated safely with highly active antiretroviral therapy [4].
  • In the interim, decisions regarding retreatment with PEG IFN and RBV should be made on a case-by-case basis after considering the tolerability of prior treatment, the severity of underlying liver disease, and the anticipated likelihood of response [17].
  • Treatment with intravenous and intraventricular injections of high doses of lymphoblastoid interferon alfa in three patients and tribavirin in one patient [18].


  1. Water intoxication after nebulised tribavirin. Titus Boher, J., Pérez Alvarez, F., Arcalà Bares, L.I. Lancet (1995) [Pubmed]
  2. Continuous aerosolised tribavirin for respiratory syncytial virus infection in lung transplant recipients. Murris-Espin, M., Didier, A., Carre, P., Icart, J., Henry, S., Leophonte, P. Lancet (1993) [Pubmed]
  3. Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Andrade, R.J., González, F.J., Vázquez, L., Cilvetti, A., Camargo, R., García-Cortés, M., Martos-VanDussen, J.V., Rosón, P., Lucena, M.I., Clavijo, E. Antivir. Ther. (Lond.) (2006) [Pubmed]
  4. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. Nasti, G., Di Gennaro, G., Tavio, M., Cadorin, L., Tedeschi, R.M., Talamini, R., Carbone, A., Tirelli, U. AIDS (2001) [Pubmed]
  5. U.S. veterans' experience with rebetron in a nonstudy environment: success or failure? Morelli, J., Kim, C.Y., Willner, I.R. Am. J. Gastroenterol. (2002) [Pubmed]
  6. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. Moucari, R., Ripault, M.P., Oulès, V., Martinot-Peignoux, M., Asselah, T., Boyer, N., El Ray, A., Cazals-Hatem, D., Vidaud, D., Valla, D., Bourlière, M., Marcellin, P. J. Hepatol. (2007) [Pubmed]
  7. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Angelico, M., Petrolati, A., Lionetti, R., Lenci, I., Burra, P., Donato, M.F., Merli, M., Strazzabosco, M., Tisone, G. J. Hepatol. (2007) [Pubmed]
  8. Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. Chang, K.O., George, D.W. J. Virol. (2007) [Pubmed]
  9. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Missiha, S., Heathcote, J., Arenovich, T., Khan, K. Am. J. Gastroenterol. (2007) [Pubmed]
  10. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. Fujita, N., Sugimoto, R., Motonishi, S., Tomosugi, N., Tanaka, H., Takeo, M., Iwasa, M., Kobayashi, Y., Hayashi, H., Kaito, M., Takei, Y. J. Hepatol. (2008) [Pubmed]
  11. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. McHutchison, J.G., Shiffman, M.L., Cheung, R.C., Gordon, S.C., Wright, T.L., Pottage, J.C., McNair, L., Ette, E., Moseley, S., Alam, J. Antivir. Ther. (Lond.) (2005) [Pubmed]
  12. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Berenguer, M., Palau, A., Fernandez, A., Benlloch, S., Aguilera, V., Prieto, M., Rayón, J.M., Berenguer, J. Liver Transpl. (2006) [Pubmed]
  13. Successful treatment of giant cell hepatitis with Rebetron (interferon/ribavirin). Liu, J.J., Piper, J.K., Glickman, J.N., Farraye, F.A. Am. J. Gastroenterol. (2003) [Pubmed]
  14. Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C. Ahern, M., Imperial, J., Lam, S. Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates. (2004) [Pubmed]
  15. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Dahari, H., Markatou, M., Zeremski, M., Haller, I., Ribeiro, R.M., Licholai, T., Perelson, A.S., Talal, A.H. J. Hepatol. (2007) [Pubmed]
  16. Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C. Panasiuk, A., Prokopowicz, D., Panasiuk, B. World J. Gastroenterol. (2004) [Pubmed]
  17. Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Fontana, R.J. Gastroenterol. Clin. North Am. (2004) [Pubmed]
  18. Failure of interferon alfa and tribavirin in rabies encephalitis. Warrell, M.J., White, N.J., Looareesuwan, S., Phillips, R.E., Suntharasamai, P., Chanthavanich, P., Riganti, M., Fisher-Hoch, S.P., Nicholson, K.G., Manatsathit, S. BMJ (1989) [Pubmed]
WikiGenes - Universities